PETVIVO HOLDINGS INC WTS - PETVW STOCK NEWS

PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) reported its financial results for the fiscal year ended March 31, 2022. Total revenues reached $115,586, a significant increase from $12,578 in the prior year, driven by the commercialization of its lead product, Spryng™. However, the company incurred an operating loss of $5,056,528 due to increased sales and marketing expenses totaling $4,970,960. The net loss for fiscal 2022 was $5,014,995, matching a loss of $0.57 per share, with cash reserves reported at $6.1 million.

PetVivo Holdings has entered a definitive distribution agreement with MWI Animal Health to promote its product, Spryng with OsteoCushion Technology, across the U.S. This partnership aims to enhance the company's presence in the animal health market, ensuring efficient distribution to veterinarians and pet owners. Spryng is designed to support joint health in companion animals, particularly addressing conditions like osteoarthritis. PetVivo is focused on innovative medical devices for animal health, holding multiple patents and a pipeline of products.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) plans to update investors on its MWI Distribution Services Agreement and share financial results for the fiscal year ending March 31, 2022. The update will occur on June 29, 2022, at 4:00 p.m. CT (5:00 p.m. ET). Attendees can access the live webcast through PetVivo's Investor Relations website, with a replay available afterward. The company, focused on innovative biomedical devices for companion animals, aims to enter the market swiftly with its products, including the lead therapy SPRYNG™ for osteoarthritis management in dogs and horses.

PetVivo Holdings (NASDAQ: PETV, PETVW) will report its financial results for the year ending March 31, 2022, on June 29, 2022, after market close. A conference call will take place at 4:00 p.m. CT to discuss these results. Investors can access the live webcast and related materials via the company's Investor Relations website. PetVivo is focused on developing medical devices and therapeutics for companion animals, emphasizing a strategy that leverages human therapies. The company has a pipeline of seventeen products and a portfolio of twenty-one patents.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW), a biomedical device company focused on pet therapeutics, will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 10:30 AM EDT. CEO John Lai will discuss the Company’s business and innovative medical devices for companion animals. The conference runs from May 23-26, 2022, at the Fontainebleau Miami Beach Hotel, with both in-person and virtual attendance options. PetVivo has a diverse product pipeline, including the SPRYNG^™ product for joint health in pets, supported by a strong patent portfolio.

PetVivo Holdings (NASDAQ:PETV, PETVW) will present at the Planet MicroCap Showcase 2022 on May 4, 2022, at 1 PM PDT in Las Vegas. CEO John Lai will discuss the company's innovative veterinary product, Spryng with OsteoCushion Technology, designed to manage joint issues in pets. The company offers a range of treatments for companion animals and holds numerous patents. Attendees can access the live presentation via a provided webcast link. For further engagement, 1on1 investor meetings are available during the conference.

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has appointed Rachael Schumaker as the new Business Development Manager for the Midwest Region. With over 20 years in veterinary product management and marketing, Schumaker's experience aims to enhance the introduction of the company's product, Spryng with OsteoCushion technology, to veterinarians. CEO John Lai noted this addition is crucial for achieving both short and long-term goals. PetVivo focuses on innovative medical devices for companion animals and has a product pipeline of 17 offerings, with Spryng already available for veterinarians.

PetVivo Holdings, Inc. (NASDAQ: PETV) announced the appointment of David J. Gregory as the new Regional Sales Manager for the Midwest U.S. His extensive experience in veterinary product management and distribution is expected to enhance the sales of PetVivo's product Spryng, which utilizes OsteoCushion technology for treating joint-related conditions in animals. CEO John Lai expressed confidence in Gregory's ability to drive sales, contributing to the company's goals surrounding this innovative veterinary medical device.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) has appointed Cliff Smith as the new Regional Sales Manager for the Southeast United States. With over 25 years of experience in veterinary product distribution, Smith aims to drive sales of PetVivo's innovative veterinary medical device, Spryng, which employs OsteoCushion technology. CEO John Lai stated that Smith's expertise will be vital in achieving the company's sales objectives. PetVivo is focused on veterinary devices and has a portfolio of seventeen products, including Spryng, designed to enhance the well-being of companion animals.